Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Dipraglurant · ADX-48621

Small molecule · developed by Addex Pharma

Phase 2/3 Most advanced trial (none active)

ADXN Developer

2 Registered trials

What is Dipraglurant?

Dipraglurant is an investigational small-molecule drug studied in Parkinson's Disease, Parkinson Disease, Dyskinesia, Drug-Induced.

At a glance

Also known as: ADX-48621
Drug type: Small molecule
Therapy area: Neurology
Developer: Addex Pharma S.A. (ADXN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: CV8JZR21A1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05116813	Phase 2/3	Parkinson Disease	Terminated	ADXN
NCT01336088	Phase 2	Parkinson's Disease	Completed	ADXN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dyskinesia, Drug-InducedDyskinesiasParkinson DiseaseParkinson's Disease

More from Addex Pharma

ADX10059 Phase 2

Sources

ClinicalTrials.gov NCT05116813

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADXN page.

Follow ADXN, the company behind Dipraglurant

See ADXN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADXN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z